Simponi golimumab regulatory update

EMA’s CHMP recommended expanding the label of Simponi golimumab from Johnson & Johnson to include treatment of polyarticular juvenile idiopathic arthritis (JIA). J&J is seeking approval of the mAb against tumor necrosis factor (TNF) alpha in combination with methotrexate in children with a body weight of >=40 kg who have responded inadequately to previous therapy with methotrexate. ...